about
Ventricular assist devices: pharmacological aspects of a mechanical therapyBridge to removal: a paradigm shift for left ventricular assist device therapy.Evidence of Glycolysis Up-Regulation and Pyruvate Mitochondrial Oxidation Mismatch During Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and ConditioningGroup III/IV muscle afferents impair limb blood in patients with chronic heart failure.Understanding exercise-induced hyperemia: central and peripheral hemodynamic responses to passive limb movement in heart transplant recipients.Characterization of diffuse fibrosis in the failing human heart via diffusion tensor imaging and quantitative histological validation.Baseline red blood cell osmotic fragility does not predict the degree of post-LVAD hemolysis.Hemodynamic responses to small muscle mass exercise in heart failure patients with reduced ejection fraction.Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009.Effect of ABO-incompatible listing on infant heart transplant waitlist outcomes: analysis of the United Network for Organ Sharing (UNOS) database.Utility of virtual crossmatch in sensitized patients awaiting heart transplantation.Heart failure and movement-induced hemodynamics: partitioning the impact of central and peripheral dysfunction.Further Peripheral Vascular Dysfunction in Heart Failure Patients With a Continuous-Flow Left Ventricular Assist Device: The Role of Pulsatility.Vascular function and the role of oxidative stress in heart failure, heart transplant, and beyond.Predictors of 30-day post-transplant mortality in patients bridged to transplantation with continuous-flow left ventricular assist devices--An analysis of the International Society for Heart and Lung Transplantation Transplant RegistryImpact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns.Impact of donor left ventricular hypertrophy on survival after heart transplant.Bridge to recovery: understanding the disconnect between clinical and biological outcomes.Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action.Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 StudyMagnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery.Ventricular assist devices or inotropic agents in status 1A patients? Survival analysis of the United Network of Organ Sharing database.ISHLT International Registry for Heart and Lung Transplantation - three decades of scientific contributions.The detection and role of circulating antibodies in rejection.Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials.Pharmacologic therapies for acute cardiogenic shock.Donor evaluation in heart transplantation: The end of the beginning.Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and MedicThe Mechanoreflex and Hemodynamic Response to Passive Leg Movement in Heart FailureInternational Society for Heart and Lung Transplantation Donation After Circulatory Death Registry Report.Lung transplantation using controlled donation after circulatory death donors: Trials and tribulations.Report From the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States.Exertional Angina Due To Fused Aortic Bioprosthesis During Left Ventricular Assist Device Support: Two Cases and Review of the Literature.Physiologic effects of continuous-flow left ventricular assist devices.Outcomes of adolescent recipients after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation Registry.ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis.Donor-recipient size matching and mortality in heart transplantation: Influence of body mass index and gender.Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods.Early screening for antibody-mediated rejection in heart transplant recipients.
P50
Q27002612-A6C16AA7-9C8F-4A45-8B28-FFBBF053C63FQ27691340-41C756E2-5383-4A56-97DB-6AF84CB34F2FQ33651722-DB5A4BED-0860-4E68-971B-146C21D35FECQ33822116-0DD8CA37-3165-448D-AFBC-7ED0E275B732Q34357729-D42D9292-6653-4B35-ADF2-58468CB10D62Q34432633-BD598214-041F-403D-97EF-9A7D46508256Q34556967-B43CE17A-8ABD-47B3-BE5D-9530D4FA4E4DQ34790165-0A8778F2-1812-4F8B-BC74-04D29ACFD91EQ34994108-1821B831-CEBA-46B2-8B8C-A412DF38533EQ35005285-CB569F1A-3C5E-4511-9314-E7A1309565ABQ35005310-7AB0B61F-437A-49B3-A968-20BE5EA18595Q35005314-AB605869-C671-4FE6-AC3C-85E9859D70E1Q35040427-F78DEA57-C7C4-4843-9D9F-8BEC88804FE8Q36055153-EACAF278-BAE4-499A-98C4-D613A47D32BDQ36170211-A26042A9-2DEF-4444-8B42-ABCF55188F4FQ36479907-4733029E-0AAE-47A6-ADB9-CF3206EB05BDQ36650205-F158D647-27E0-4F97-BB75-57362A590D89Q36700563-9A00069D-1B1A-47B3-8587-406B9812080BQ37021774-9B70DA86-E34F-4E2E-B0BC-0559898CE968Q37021783-37619274-9A92-43BF-92AF-CC04B6E74E0BQ37101630-7AD26D92-1723-4D24-80E0-3C461A806620Q37286036-79343981-81D6-4157-BEED-D7BC30F7ED44Q37685852-1552FA1F-8976-4345-8669-78845D716DB3Q38086948-92826136-4A8D-4D42-AEA0-98AE9D4AF87EQ38133319-0295D855-C4C8-497D-B268-1442F665C667Q38200406-B0096AEF-71F8-45FB-BE54-A72985FF8809Q38200874-19E408CA-7A3A-44F0-9152-D59D9EA1A727Q38228292-464D80DE-2292-472A-A838-2154D095DB29Q38377279-0C79C19A-8E9F-4148-ADDC-976078F7E054Q38570830-7FCC0657-D140-41C6-9E64-3EF5E90D6A72Q38603844-CFD2A533-9BDA-4CE3-B63F-A3D3CEECF46CQ38629127-CBA69D9A-A6E6-4D80-9400-5102A5B62A41Q38683178-6A693266-FF11-4E7E-BFBB-D753DEBFF77DQ38775451-A33F6E3E-B451-41AC-8FB9-D6DC223B2FD0Q38845132-13FF0A53-398F-4DD5-AE23-CEA4D11D6F0DQ38892709-E40CD205-CDE2-477E-A6B7-F199B2FAA1A1Q38896093-54E93C48-1B28-4CDD-9009-245B5A6E9502Q38929461-8D31C1F8-26B1-4A18-880D-CE5CC1B8FE2EQ38970428-B9421E12-EACA-4959-AEAB-A073C30FE158Q39101185-460C72FF-3A22-4814-9228-7B7DA27AE468
P50
description
researcher ORCID ID = 0000-0002-7362-0513
@en
wetenschapper
@nl
name
Josef Stehlik
@ast
Josef Stehlik
@en
Josef Stehlik
@es
Josef Stehlik
@nl
type
label
Josef Stehlik
@ast
Josef Stehlik
@en
Josef Stehlik
@es
Josef Stehlik
@nl
prefLabel
Josef Stehlik
@ast
Josef Stehlik
@en
Josef Stehlik
@es
Josef Stehlik
@nl
P106
P1153
35278731300
P21
P31
P496
0000-0002-7362-0513